The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
Open accessAbstract
OBJECTIVE: To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications. RESEARCH DESIGN AND METHODS: Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR). RESULTS: Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22). ROR was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82–6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs (6 and 4, respectively). CONCLUSIONS: In agreement with preclinical and clinical studies, AERS analysis is consistent with an association between pioglitazone and bladder cancer. This issue needs constant epidemiologic surveillance and urgent definition by more specific studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is also some suggestion of a possible link between pioglitazone and bladder cancer and therefore individuals with a history of bladder cancer or unexplained hematuria should probably not receive this drug.98,99”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [98]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
van Puijenbroek, E., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, T. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,385
Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases
Pariente, A., Grégoire, F., Fourrier‐Réglat, A., Haramburu, F., & Moore, N. D. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00007 · Cited by 270
Perspectives on the Use of Data Mining in Pharmacovigilance
Almenoff, J. S., Tonning, J. M., Gould, A. L., Szarfman, A., Hauben, M., Ouellet‐Hellstrom, R., Ball, R., Hornbuckle, K., Walsh, L., Yee, C., et al. (2005) · Drug Safety · doi:10.2165/00002018-200528110-00002 · Cited by 251
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 228
Moore, N., Kreft-Jaïs, C., Haramburu, F., Noblet, C., Andréjak, M., Ollagnier, M., & Bégaud, B. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00615.x · Cited by 134
Antimicrobials and the Risk of Torsades de Pointes
Poluzzi, E., Raschi, E., Motola, D., Moretti, U., & Ponti, F. D. (2010) · Drug Safety · doi:10.2165/11531850-000000000-00000 · Cited by 123
Self-citation???Extreme Duplication??? in the US FDA Adverse Events Reporting System Database
Hauben, M., Reich, L., DeMicco, J., & Kim, K. K. (2007) · Drug Safety · doi:10.2165/00002018-200730060-00009 · Cited by 79
Suzuki, S., Arnold, L. L., Pennington, K. L., Kakiuchi-Kiyota, S., Wei, M., Wanibuchi, H., & Cohen, S. M. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp256 · Cited by 79
Cited by
Sorted by citations
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,071
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Metadata
- Authors
- Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Poluzzi, Elisabetta
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-05-20
- Volume
- 34
- Issue
- 6
- Pages
- 1369-1371
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3114317
- OpenAlex
- W2133104620
- Cited by
- 239
- References
- 12
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 14 · 2015: 20 · 2014: 23 · 2013: 37 · 2012: 60
- FWCI
- 56.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pioglitazone, bladder cancer, drug adverse events, antidiabetic drugs, FDA Adverse Event Reporting System, reporting odds ratio, insulin, metformin, glimepiride, exenatide, gliclazide, acarbose, drug safety
- MeSH terms
- Pioglitazone, Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, United States, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
